Recent Updates
Recently added Catalysts

SP-420

Phase 2

Beta Thalassemia Major Anemia | Small molecule | Oncology |Icon Plc|Last Updated: Sep 24, 2025

Success Probability
Subscribe to view
Market & Valuation
Subscribe to view
Trial Design
RandomizedCONTROLLEDDMC
Total Trials1
Total Enrollment90
FDA Designations
No designations recorded
Clinical trial landscape

SP-420 · 1 trial · 2 indications

Phase 2 1
NCT05693909A Trial Testing SP-420 in Subjects With Transfusion-dependent β-thalassemia or Low-risk Myelodysplastic SyndromesBeta Thalassemia Major Anemia
RECRUITING90 Analytics
PHASE2RECRUITING
A Trial Testing SP-420 in Subjects With Transfusion-dependent β-thalassemia or Low-risk Myelodysplastic Syndromes
Beta Thalassemia Major Anemia
NCT0569390990
Unlock trial analytics
Study Endpoints
Primary Endpoints
To establish dose-response relationship of SP-420 for 24 weeks in the treatment of subjects with transfusion-dependent β-thalassemia
24 weeks
To assess the safety and tolerability of ascending doses of SP-420 after 12 weeks treatment of subjects with transfusion-dependent low-risk myelodysplastic syndrome
12 weeks
Secondary Endpoints
To assess the efficacy of SP-420 in clearing iron from the liver after 24 weeks treatment of subjects with transfusion-dependent β-thalassemia
24 weeks
To assess the efficacy of SP-420 in clearing iron from the liver after 12 and 48 weeks treatment of subjects with transfusion-dependent β-thalassemia
12 and 48 weeks
To assess the efficacy of SP-420 on serum (s-) ferritin
up to 48 weeks
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingNONE
ModelSEQUENTIAL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
Cohort 1a-1bEXPERIMENTALSP-420 for 48 weeks
Cohort 2a-2bEXPERIMENTALSP-420 for 48 weeks
Cohort 3a-3bEXPERIMENTALSP-420 for 48 weeks
1c-1dEXPERIMENTALSP-420 for 48 weeks
2c-2dEXPERIMENTALSP-420 for 48 weeks
3c-3dEXPERIMENTALSP-420 for 48 weeks
Interventions
NameTypeDescription
SP-420DRUGCapsules for oral intake
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites1

Thalassemia cohorts: Inclusion criteria: * Women and men aged 18 years or older * Transfusion-dependent β-thalassemia including HbE/β-thalassemia requiring iron chelation therapy (β-thalassemia with mutation and/or multiplication of α-globin is allowed) * On a stable dose of iron chelation for at ...

Countries:Denmark
Unlock Eligibility Criteria
Recent Changes (Last 90 Days)
LOWMay 26, 2026NCT05693909primaryCompletionDate: changed
LOWMay 24, 2026NCT05693909studyFirstPostDate: changed